Jeffrey Capello, executive vice president and chief financial officer, divulged that Biogen intends to exercise its option to increase its stake in the Samsung Bioepis joint venture. Currently, Samsung BioLogics holds 94.6% of the company, and Biogen owns the remaining 5.4%.
Biogen, one partner in the biosimilar development company Samsung Bioepis, reported total revenues of $3.1 billion in its first quarter 2018 business update call. While most of Biogen’s earnings—up 11% from the same period in 2017—derived from its drugs targeting multiple sclerosis, Jeffrey Capello, executive vice president and chief financial officer, said that biosimilars brought in $128 million in revenues, up from $66 million in the first quarter of 2017.
Approximately 80,000 patients are now taking Biogen’s biosimilars, said Capello, and the uptake of Benepali, a European Medicines Agency—approved etanercept biosimilar referencing Enbrel, is estimated to have produced an €800 million (approximately $970 million) annual savings in Europe.
Biogen sees the potential for even greater biosimilar growth ahead; earlier this month, together with Samsung, Biogen reached an agreement with AbbVie, the maker of the reference adalimumab (Humira). The settlement ended patent litigation over the reference drug and will allow commercialization of Samsung Bioepis’ approved adalimumab biosimilar, Imraldi, in Europe beginning in October 2018. Capello said that the adalimumab biosimilar will be a growth driver for the business in the days ahead.
Capello also divulged that Biogen intends to exercise its option to increase its stake in the Samsung Bioepis joint venture. Currently, Samsung BioLogics holds 94.6% of the company, and Biogen owns the remaining 5.4%. According to Reuters, Biogen has the option to increase its stake in the joint company to as much as 49.9%. That investment, says Korean media outlet The Investor, could be worth as much as $370 million.
Currently, Samsung Bioepis’ pipeline includes etanercept, infliximab (approved and launched in the United States as Renflexis), adalimumab, insulin glargine (tentatively approved in the United States as a follow-on insulin product), trastuzumab (for which a Biologics License Application was filed with the FDA in late 2017), and bevacizumab.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.